The global spotlight on healthcare innovation continues to grow, and one venture capital firm in Shanghai is doubling down on its commitment.
Med-Fine Capital has just wrapped up its second USD-denominated fund, aiming to back the next generation of biotech and healthcare startups in China.
Backed by a Diverse Group of Global Investors
This latest fund attracted a wide range of limited partners (LPs), showing just how much interest there is in China’s booming healthcare tech scene.
Contributors included well-known global fund-of-funds (FOFs), major financial institutions from Hong Kong, family offices in Singapore, and several big-name corporations rooted in the healthcare industry.
The broad investor base underscores the strong belief in Med-Fine’s vision for the future of medical innovation.
Staying Committed to Biotech and Cutting-Edge Health Technologies
With fresh capital in hand, Med-Fine Capital plans to keep doing what it does best—identifying and supporting early-stage startups working on groundbreaking biotech, diagnostics, digital health solutions, medical devices, and broader healthcare services.
The goal is to help these emerging companies scale their technology and bring real value to the healthcare landscape, both in China and potentially beyond.
Experienced Leadership Steers the Ship
The firm is led by Managing Partner Jack Zhou, alongside Dr. Vince Deng, who heads up biotech investments.
Together, they bring deep industry insight and investment expertise, positioning the firm to make strategic bets on high-potential startups.
Under their guidance, Med-Fine Capital has built a reputation for spotting early winners and nurturing them through critical growth phases.
Over 60 Portfolio Companies and Counting
Since its inception, Med-Fine Capital has already backed more than 60 healthcare-related companies.
Some standout names in their portfolio include Mabworks, Eccogene, Zion, LYNK, Pharma Legacy, MagAssist, Alebund, Allorion, ImmVira, Degron, Allink, and Castalysis.
Each of these companies plays a role in transforming the healthcare landscape, from advanced therapeutics to precision diagnostics and medical hardware innovation.
Looking Ahead: What’s Next?
With the new fund secured, Med-Fine Capital is in a strong position to continue making waves in the early-stage healthcare space.
Their strategy of pairing scientific understanding with smart capital deployment is expected to keep yielding impressive results.
As the biotech and medtech ecosystems continue to evolve, all eyes will be on which startups they back next—and how those innovations will shape the future of health and wellness.